Charles River Laboratories International (NYSE:CRL) Lowered to Market Perform Rating by William Blair

Charles River Laboratories International (NYSE:CRL) was downgraded by equities research analysts at William Blair from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday,Finviz reports. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.40 EPS.

Other equities analysts also recently issued research reports about the stock. UBS Group restated a “neutral” rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Citigroup downgraded Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price target for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective for the company. in a research report on Monday, November 18th. TD Cowen upped their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Finally, Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $209.00.

Charles River Laboratories International Trading Up 3.9 %

Shares of NYSE CRL opened at $169.84 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $8.68 billion, a PE ratio of 21.26, a PEG ratio of 5.75 and a beta of 1.38. Charles River Laboratories International has a twelve month low of $160.85 and a twelve month high of $275.00. The stock has a fifty day simple moving average of $188.58 and a 200-day simple moving average of $197.93.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the company posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. On average, equities analysts forecast that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Large investors have recently modified their holdings of the stock. American Century Companies Inc. raised its position in Charles River Laboratories International by 4.6% during the 2nd quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock worth $1,354,000 after buying an additional 291 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in Charles River Laboratories International by 74.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock worth $833,000 after purchasing an additional 1,721 shares in the last quarter. Amalgamated Bank lifted its position in Charles River Laboratories International by 21.7% in the second quarter. Amalgamated Bank now owns 13,036 shares of the medical research company’s stock valued at $2,693,000 after purchasing an additional 2,323 shares during the period. Canada Pension Plan Investment Board purchased a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $124,000. Finally, ProShare Advisors LLC increased its position in Charles River Laboratories International by 6.2% during the 2nd quarter. ProShare Advisors LLC now owns 9,975 shares of the medical research company’s stock worth $2,061,000 after purchasing an additional 583 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).